- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01116544
Treatment of Chronic Stroke With AMES + EMG Biofeedback (AMES)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hemispheric stroke (ischemic or hemorrhagic), cortical or sub-cortical, documented by either a CT or MRI scan and associated with residual upper extremity weakness.
- Chronic stroke, occurring ≥12 months prior to subject enrollment.
- Age 18-80 years old.
- Inability to move any of the fingers of the affected hand more than 5.0 cm into extension.
- Finger-and-wrist impedance ≤3 on the Modified Ashworth Scale.
- Measureable EMG (>2 x baseline) in the long finger extensor muscle during attempted hand opening or closing.
- Physically and cognitively capable of consenting to and complying with the protocol (based on exam by Study Physician).
- Subject must be physically capable of communicating informed consent or must be accompanied by legally authorized representative to provide informed consent.
Exclusion Criteria:
- Complete flaccidity of the affected arm.
- Significant upper extremity proprioceptive deficit (<70% correct detection of the direction of passive finger movement with eyes closed).
- Pathological neurological/physical conditions, other than stroke, impairing the function of the impaired arm or resulting in pain in the arm.
- Spinal cord injury, arthritis, or fractures of affected arm that have resulted in loss of range of motion.
- Peripheral nerve injury or neuropathy resulting in significant motor or sensory loss in the tested arm.
- Cardiopulmonary compromise including but not limited to uncontrolled hypertension or angina, deep vein thrombosis, decompensated congestive heart failure, myocardial infarction, heart irregularities, or exercise intolerance.
- Major active psychiatric disorder.
- Cognitively or behaviorally unable to follow instructions including severe apraxia; inability to understand verbal (English) directions, or inability to communicate adequately with study personnel.
- Size of arm incompatible with the AMES device (checked by placing the limb in the device).
- Severe contractures or decreased range of motion or skin condition that would prohibit comfortable positioning or tolerance of the device or the vibrators.
- Any progressive neurodegenerative disorder affecting the upper extremity motor system.
- Uncontrolled seizure disorder.
- Current abuse of alcohol or drugs.
- Terminal illness with anticipated survival of <12 months.
- Current or planned concurrent participation in another study involving therapy to the impaired arm
- Planned initiation of or cessation of any kind of clinical therapy to the impaired limb just prior to or during the AMES treatment period.
- NIH Stroke Scale, following scores: Sensory Item score of >1; Neglect involving the affected limb score >1.
- Intent to receive Botox injections (5 months prior to or during enrollment), initiation of antispasmodic medication, or use of any other robotic (e.g., MANUS, Locomat) or electrical or vibratory stimulation device (e.g., Bioness) while participating in the AMES trial.
- Cognitively or behaviorally unable to follow instructions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: AMES therapy with EMG biofeedback
The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand.
The subjects job is to attempt to assist the device in the movement.
A computer screen will provide visual feedback of the amount of EMG activity the subject is able to generate in the hand.
This study will examine whether AMES therapy combined with EMG biofeedback can restore hand opening to plegic stroke subjects.
|
Each subject will receive 30 sessions of AMES therapy in the clinic.
Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device.
One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback.
While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
Other Names:
|
|
Experimental: AMES therapy with Torque biofeedback
The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand.
The subjects job is to attempt to assist the device in the movement.
A computer screen will provide visual feedback of the amount of torque (force) the subject is able to generate in the hand during the movement.
This study will examine whether AMES therapy combined with Torque biofeedback can restore hand opening to plegic stroke subjects.
|
Each subject will receive 30 sessions of AMES therapy in the clinic.
Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device.
One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback.
While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Box and Blocks Test
Time Frame: Within a week of completing all training sessions.
|
Measurement of the change in functional movement of the hand associated with 30 AMES training sessions.
|
Within a week of completing all training sessions.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fugl-Meyer (UL) Assessment
Time Frame: At baseline and again within a week of completing all training sessions. The interval between measurements was 10-12 weeks.
|
Scale: Fugl-Meyer Assessment-Motor Function-Upper Limb Measurement of impairment in the upper limb based on tone, range-of-motion, and synergies.
Total score in this study includes only the Upper Limb portion of the Motor Function subscale of the assessment, the Upper Limb subset having a scoring range of 0-66, with 0 representing no function and no visible reflexes (i.e., profound plegia) and 66 representing normal motor function.
|
At baseline and again within a week of completing all training sessions. The interval between measurements was 10-12 weeks.
|
|
Stroke Impact Scale (Physical Problems, Mobility, Hand, ADL)
Time Frame: Within a week of completing all training sessions.
|
Four of 8 possible subscales were used: Physical Problems, Mobility, Hand, and Daily Living, consisting of 26 total questions [scored from 1 (least impact) to 5 (most impact)]. The total (summed) raw score for all 4 sub-scales has a minimum of 26 and maximum of 130. The total raw score is then transformed: [(Actual Raw Score-Lowest Possible Raw Score)/Possible Raw Score Range] X 100. The minimum transformed score is 0 and the maximum is 100. |
Within a week of completing all training sessions.
|
|
Stroke Impact Scale (Stroke Recovery)
Time Frame: Within a week of completing all training sessions.
|
A separate section of the Stroke Impact Scale measures self-perception of stroke recovery.
Stroke recovery is based on a scale of 0-100, with 0 representing no recovery and 100 representing full recovery.
|
Within a week of completing all training sessions.
|
|
Strength Test Flexion
Time Frame: At baseline and again within a week of completing all training sessions. The interval between measurements was 10-12 weeks.
|
Maximum squeezing (i.e., flexion) strength for thumb and fingers at the end of each training session.
The participant squeezed the hand as hard as possible 3 times with a 5-10 second rest period between each effort.
A single score was calculated for each training session as the average of the 3 efforts.
Baseline score was based on the average of the first 3 session scores (i.e., 9 total efforts over the first 3 training sessions).
Final score was based on the average of the last 3 training sessions.
|
At baseline and again within a week of completing all training sessions. The interval between measurements was 10-12 weeks.
|
|
Strength Test Extension
Time Frame: At baseline and again within a week of completing all training sessions. The interval between measurements was 10-12 weeks.
|
Maximum opening (i.e., extension) strength for thumb and fingers at the end of each training session.
The participant squeezed the hand as hard as possible 3 times with a 5-10 second rest period between each effort.
A single score was calculated for each training session as the average of the 3 efforts.
Baseline score was based on the average of the first 3 session scores (i.e., 9 total efforts over the first 3 training sessions).
Final score was based on the average of the last 3 training sessions.
|
At baseline and again within a week of completing all training sessions. The interval between measurements was 10-12 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Paul J. Cordo, PhD, Oregon Health and Science University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT NS060192
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
Clinical Trials on AMES Therapy (assisted movement and enhanced sensation)
-
Shirley Ryan AbilityLabActive, not recruitingStroke | HealthyUnited States
-
Oregon Health and Science UniversityAMES TechnologyTerminated
-
SatasairaalaRecruiting
-
Swiss Federal Institute of TechnologyCentre Hospitalier Universitaire Vaudois; Swiss Commission for Technology and...Unknown
-
King Abdulaziz UniversityCompletedAccelerate Tooth Movement
-
University of Alabama at BirminghamUnited States Department of DefenseCompletedTraumatic Brain InjuryUnited States
-
Ziauddin UniversityNot yet recruiting
-
Riphah International UniversityCompletedChronic StrokePakistan
-
University of ChileClinica Indisa; Hospital de Urgencia y Asistencia PúblicaRecruitingCritical Illness MyopathyChile
-
Fudan UniversityNot yet recruiting